NCT03310918Active, not recruiting
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
Randomized Trial of a Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- First submitted
- 2 Oct 2017
- Start date
- 31 Oct 2017
- Primary completion date
- 1 Apr 2023
- Lead sponsor
- Massachusetts General Hospital
- NCT number
- NCT03310918
What you commit to
- Study type: Interventional
- Planned participants: 320
- From 31 Oct 2017 to the primary completion date, 1 Apr 2023
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients not receiving care at MGH
- Patients receiving intensive chemotherapy (requiring 4-6 week hospitalization)
- Patients receiving supportive care alone
- Patients already receiving palliative care
Other illness
- Major psychiatric illness or co-morbid conditions prohibiting compliance with study procedures
Who the study is looking for
- Patients with AML receiving non-intensive therapy including hypomethylating agents, single-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents offered on a clinical trial, including the following populations:
- Newly diagnosed AML
- Relapsed AML
- Primary refractory AML
- The ability to provide informed consent
- The ability to comprehend English or complete questionnaires with minimal assistance of an interpreter
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Ohio State University Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.